289 related articles for article (PubMed ID: 20937115)
21. Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells.
Deng X; Terunuma H; Nieda M; Xiao W; Nicol A
Int Immunopharmacol; 2012 Dec; 14(4):593-605. PubMed ID: 23063974
[TBL] [Abstract][Full Text] [Related]
22. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes.
Schleypen JS; Von Geldern M; Weiss EH; Kotzias N; Rohrmann K; Schendel DJ; Falk CS; Pohla H
Int J Cancer; 2003 Oct; 106(6):905-12. PubMed ID: 12918068
[TBL] [Abstract][Full Text] [Related]
23. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
[TBL] [Abstract][Full Text] [Related]
24. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
[TBL] [Abstract][Full Text] [Related]
25. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
26. Anti-West Nile virus activity of in vitro expanded human primary natural killer cells.
Zhang M; Daniel S; Huang Y; Chancey C; Huang Q; Lei YF; Grinev A; Mostowski H; Rios M; Dayton A
BMC Immunol; 2010 Jan; 11():3. PubMed ID: 20089143
[TBL] [Abstract][Full Text] [Related]
27. Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies.
Besser MJ; Shoham T; Harari-Steinberg O; Zabari N; Ortenberg R; Yakirevitch A; Nagler A; Loewenthal R; Schachter J; Markel G
PLoS One; 2013; 8(3):e57922. PubMed ID: 23483943
[TBL] [Abstract][Full Text] [Related]
28. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components.
Alici E; Sutlu T; Björkstrand B; Gilljam M; Stellan B; Nahi H; Quezada HC; Gahrton G; Ljunggren HG; Dilber MS
Blood; 2008 Mar; 111(6):3155-62. PubMed ID: 18192509
[TBL] [Abstract][Full Text] [Related]
29. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
Collins SM; Bakan CE; Swartzel GD; Hofmeister CC; Efebera YA; Kwon H; Starling GC; Ciarlariello D; Bhaskar S; Briercheck EL; Hughes T; Yu J; Rice A; Benson DM
Cancer Immunol Immunother; 2013 Dec; 62(12):1841-9. PubMed ID: 24162108
[TBL] [Abstract][Full Text] [Related]
30. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
Pahl JH; Ruslan SE; Buddingh EP; Santos SJ; Szuhai K; Serra M; Gelderblom H; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
Clin Cancer Res; 2012 Jan; 18(2):432-41. PubMed ID: 22090361
[TBL] [Abstract][Full Text] [Related]
31. In Vitro Killing of Colorectal Carcinoma Cells by Autologous Activated NK Cells is Boosted by Anti-Epidermal Growth Factor Receptor-induced ADCC Regardless of RAS Mutation Status.
Turin I; Delfanti S; Ferulli F; Brugnatelli S; Tanzi M; Maestri M; Cobianchi L; Lisini D; Luinetti O; Paulli M; Perotti C; Todisco E; Pedrazzoli P; Montagna D
J Immunother; 2018 May; 41(4):190-200. PubMed ID: 29293164
[TBL] [Abstract][Full Text] [Related]
32. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
33. Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity.
van Hauten PMM; Hooijmaijers L; Vidal-Manrique M; van der Waart AB; Hobo W; Wu J; Blijlevens NMA; Jansen JH; Walcheck B; Schaap NPM; de Jonge PKJD; Dolstra H
Cytotherapy; 2024 Mar; 26(3):252-260. PubMed ID: 38127030
[TBL] [Abstract][Full Text] [Related]
34. Antibody-dependent cell lysis by NK cells is preserved after sarcoma-induced inhibition of NK cell cytotoxicity.
Pahl JH; Ruslan SE; Kwappenberg KM; van Ostaijen-Ten Dam MM; van Tol MJ; Lankester AC; Schilham MW
Cancer Immunol Immunother; 2013 Jul; 62(7):1235-47. PubMed ID: 23624801
[TBL] [Abstract][Full Text] [Related]
35. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
36. Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers.
Lee SC; Shimasaki N; Lim JSJ; Wong A; Yadav K; Yong WP; Tan LK; Koh LP; Poon MLM; Tan SH; Ow SGW; Bharwani L; Yap YS; Foo MZQ; Coustan-Smith E; Sundar R; Tan HL; Chong WQ; Kumarakulasinghe NB; Lieow JLM; Koe PJX; Goh BC; Campana D
Clin Cancer Res; 2020 Sep; 26(17):4494-4502. PubMed ID: 32522887
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity.
Oliviero B; Mantovani S; Varchetta S; Mele D; Grossi G; Ludovisi S; Nuti E; Rossello A; Mondelli MU
J Hepatol; 2017 Jun; 66(6):1130-1137. PubMed ID: 28192188
[TBL] [Abstract][Full Text] [Related]
38. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells.
Nham T; Poznanski SM; Fan IY; Shenouda MM; Chew MV; Lee AJ; Vahedi F; Karimi Y; Butcher M; Lee DA; Hirte H; Ashkar AA
Cancer Immunol Immunother; 2018 Apr; 67(4):575-587. PubMed ID: 29299659
[TBL] [Abstract][Full Text] [Related]
39. Phenotype and Function of Activated Natural Killer Cells From Patients With Prostate Cancer: Patient-Dependent Responses to Priming and IL-2 Activation.
Hood SP; Foulds GA; Imrie H; Reeder S; McArdle SEB; Khan M; Pockley AG
Front Immunol; 2018; 9():3169. PubMed ID: 30761160
[No Abstract] [Full Text] [Related]
40. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.
Lim SA; Kim TJ; Lee JE; Sonn CH; Kim K; Kim J; Choi JG; Choi IK; Yun CO; Kim JH; Yee C; Kumar V; Lee KM
Cancer Res; 2013 Apr; 73(8):2598-607. PubMed ID: 23580577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]